Toggle light / dark theme

The U.S. is facing an unprecedented shortage of obstetricians and gynecologists (OB/GYNs). According to the American College of Obstetricians and Gynecologists, around half of the nation’s counties don’t have access to even a single OB/GYN, which means more than 10 million women are in need of OB/GYNs for primary care. Alarmingly, there are now 8000 fewer women’s health specialists than needed, and that number is predicted rise to 22000 by mid-century.


As the nation’s largest group of Maternal-Fetal Medicine (MFM) and OB/GYN Hospitalist providers, Obstetrix Medical Group is uniquely addressing this critical issue. With multiple diverse TeleMFM programs around the country, Obstetrix provides a key solution for hospitals and community OB/GYN physicians that improves access to specialty care for women with high-risk pregnancies.

Mednax clinicians have long relied on the benefits of telehealth to complement traditional in-person care. MFM providers specifically have utilized various forms of telehealth since the late 1980s. Today, virtual care continues to play an essential role in bridging distance gaps and bringing the highest quality care to patients in need, no matter their location. Through the use Vsee, one of Mednax’s primary telehealth platform vendors, as well as others, clinicians across the country are finding a silver lining during the COVID-19 pandemic. Though helpful in any region, in the rural areas of the Mountain West, it has become even more of a blessing. We spoke with Oliver (Bill) Jones, M.D., about how telehealth integrated into their practice and how it has positively impacted their high-risk patients.

A need for change

Obstetrix Medical Group of Colorado has been practicing for over thirty years and provides outreach to Colorado, Wyoming and Nebraska— a geography that requires long travel time for either physicians or patients. Although they have been in practice for a while, using telehealth to care for patients has accelerated in use for most members of their group. Dr. Jones explains that their team flew across states to meet with their patients before the pandemic, making for very long days. In addition, the unpredictable Colorado weather sometimes affected the flight’s departures and return times. Dr. Jones laughs, remembering a particularly nasty snowstorm back in November of 2019 that jumpstarted the conversations about telehealth. The flight to Casper, Wyo., was cancelled but Dr. Jones did not want the patients to have to reschedule appointments. He worked with the sonographer to come up with an alternative solution of virtual visits.

COVID-19 was linked to brain tissue loss in a U.K. brain imaging study, according to early findings published June 15 in the preprint server medRxiv.

The study involved 782 participants, with researchers comparing brain scans from before and after COVID-19 infection. Researchers pulled data from the U.K. Biobank, which scanned more than 40000 participants before the pandemic hit the region, allowing them to invite participants back for a second imaging visit.

Findings showed tissue loss in certain parts of the brain.

Google has invested heavily in healthcare. I think in the end, they will be the ultimate profile provider for users. Just connect your electronic health record with your personal profile combined with Fitbit wearable technologies.


Google has made moves to expand its presence in the healthcare sector during the last 12 months, including multiple partnerships with health systems, several new product launches and efforts to facilitate the country’s COVID-19 vaccine rollout.

Below is a timeline of Google’s key healthcare moves reported by Becker’s Hospital Review since June 2020.

June 18, 2020: Google sister company Verily developed a program to help employees and students safely return to offices and shared spaces while monitoring for COVID-19. The program, dubbed Healthy at Work, is powered by Verily’s software and COVID-19 testing infrastructure.

An aging/longevity link, (not sure how novel)


As life expectancies around the world increase, so are the number of people who will experience age-related cognitive decline. The amount of oxygen in the blood declines with age. Aging in the brain might be naturally held at bay by adenosine receptor A2B (ADORA2B), a protein on the membrane of red blood cells which is known to help release oxygen from the blood cells so it can be used by the body.

Aging in the brain is naturally reduced by ADORA2B, which helps get oxygen to the brain when needed. Further testing will be needed to determine whether ADORA2B levels naturally decline with age and whether treatment with drugs that activate ADORA2B can reduce cognitive decline in normal mice.

The Environmental Protection Agency (EPA) will reconsider decisions underlying a rule governing emissions of a chemical that it has deemed carcinogenic following a request from an industry group.

The agency told stakeholders in letters dated last week that it would reconsider its risk information for ethylene oxide, a chemical the EPA currently says is carcinogenic if it is inhaled.

The EPA also said it would reconsider its prior decision not to use a much lower risk finding from the state of Texas as an alternative risk value.

The scientists found “biotin paint” on a protein named RSK1, which is part of a complex that keeps a nearby group of proteins, called RAS proteins, dormant. The scientists were surprised to discover that when they inactivated mutant KRAS, the nearby RSK1 complex stopped working as well. This allowed the RAS proteins to activate and take over the work of the missing mutant KRAS.


Cancer cells can become resistant to treatments through adaptation, making them notoriously tricky to defeat and highly lethal. Cold Spring Harbor Laboratory (CSHL) Cancer Center Director David Tuveson and his team investigated the basis of “adaptive resistance” common to pancreatic cancer. They discovered one of the backups to which these cells switch when confronted with cancer-killing drugs.

KRAS is a gene that drives . Most pancreatic cancers have a mutation in the KRAS protein, causing uncontrolled growth. But, drugs that shut off mutant KRAS do not stop the proliferation. The find a way to bypass the blockage and keep on dividing. Derek Cheng, the lead author of the study and a former Medical Scientist Training Program student in the Tuveson lab, compares this process to backup engines on a ship. He says, “You take away your , you’re kind of on some backup engines. But it’s getting by on those. The ship isn’t sinking yet. It’s still moving at a slower pace. Ultimately what we want to do is sink the ship.”

Tuveson and his team wanted to figure out the “backup engines” in these cells. They used a technique called biotin proximity labeling to identify what other proteins interacted with mutant KRAS. Cheng says, “I basically attach a spray can to my favorite protein, or rather least favorite protein, in this case. And so it attaches biotin, basically spraying biotin ‘paint’ to nearby proteins, and we’re able to analyze it to figure out what proteins were labeled.”

The research also found that one in 5 patients reported post-traumatic stress disorder (PTSD), with 16% presenting depressive symptoms.

The study, conducted in Italy, involved testing neurocognitive abilities and taking MRI brain scans of patients two months after experiencing COVID-19 symptoms. More than 50% of patients experienced cognitive disturbances; 16%% had problems with executive function (governing working memory, flexible thinking, and information processing), 6%… See More.


COVID-19 patients suffer from cognitive and behavioral problems two months after being discharged from hospital, a new study presented at the 7th Congress of the European Academy of Neurology (EAN) has found.

Issues with memory, spatial awareness, and information processing problems were identified as possible overhangs from the virus in post-COVID-19 patients who were followed up within eight weeks.

Engineers at Duke University have devised a system for manipulating particles approaching the miniscule 2.5 nanometer diameter of DNA using sound-induced electric fields. Dubbed “acoustoelectronic nanotweezers,” the approach provides a label-free, dynamically controllable method of moving and trapping nanoparticles over a large area. The technology holds promise for applications in the fields ranging from condensed matter physics to biomedicine.

The research appears online on June 22 in Nature Communications.

Precisely controlling nanoparticles is a crucial ability for many emerging technologies. For example, separating exosomes and other tiny biological molecules from blood could lead to new types of diagnostic tests for the early detection of tumors and neurodegenerative diseases. Placing engineered nanoparticles in a specific pattern before fixing them in place can help create new types of materials with highly tunable properties.

😀


Cellular senescence, a state of permanent growth arrest, has emerged as a hallmark and fundamental driver of organismal aging. It is regulated by both genetic and epigenetic factors. Despite a few previously reported aging-associated genes, the identity and roles of additional genes involved in the regulation of human cellular aging remain to be elucidated. Yet, there is a lack of systematic investigation on the intervention of these genes to treat aging and aging-related diseases.

How many aging-promoting genes are there in the human genome? What are the molecular mechanisms by which these genes regulate aging? Can gene therapy alleviate individual aging? Recently, researchers from the Chinese Academy of Sciences have shed new light on the regulation of aging.

Recently, researchers from the Institute of Zoology of the Chinese Academy of Sciences (CAS), Peking University, and Beijing Institute of Genomics of CAS have collaborated to identify new human senescence-promoting genes by using a genome-wide CRISPR/Cas9 screening system and provide a new therapeutic approach for treating aging and aging-related pathologies.